Barry Dicicco
Pulmonary Disease · Fairfax, VANPI 1093717324
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (43.5%), consulting fees and grants — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 37.6% of the total. Reporting peaked in 2021 at $1,928 and has fallen 89.2% since, to $208 in 2025.
Across 126 payments — averaging $40.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$2K
- Genentech, Inc.$1K
- GSK$515
- AstraZeneca$504
- Boehringer Ingelheim$233
- Mylan Specialty L.p.$190
- plus $738 from 18 others
What the payments were for
- Consulting fees$1,86937%
- Grants$1,00020%
- Food & beverage$2,21743%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 4 | $1,918 |
| Genentech, Inc. | 1 | $1,000 |
| GSK | 39 | $515 |
| AstraZeneca | 26 | $504 |
| Boehringer Ingelheim | 12 | $233 |
| Mylan Specialty L.p. | 9 | $190 |
| Teva Pharmaceuticals USA, Inc. | 7 | $115 |
| Sanofi | 5 | $109 |
| Harmony Biosciences LLC | 3 | $76 |
| Insmed, Inc. | 3 | $50 |
| Mallinckrodt Hospital Products Inc. | 2 | $49 |
| Exact Sciences | 2 | $42 |
| Actelion Pharmaceuticals US, Inc. | 2 | $41 |
| Medtronic | 1 | $36 |
| Axsome Therapeutics, Inc. | 1 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| Verona Pharma, Inc. | 1 | $29 |
| Fisher & Paykel Healthcare Inc | 1 | $25 |
| Genentech USA, Inc. | 1 | $24 |
| Merck | 1 | $19 |
| Circassia Inc. | 1 | $17 |
| Advanced Respiratory, Inc | 1 | $14 |
| Amgen | 1 | $13 |
| Electromed, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,097 in reported general payments places this provider in the 60th percentile of 317 pulmonary disease providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $32,066 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $26,619 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $9,986 |
| Spiriva RespimatTiotropium Bromide | 19 | $9,133 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 18 | $5,120 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 81 | $2,279 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,142 |
| Fluticasone Propionate | 21 | $277 |
| Montelukast Sodium | 33 | $223 |
| Prednisone | 41 | $147 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $56 |
| Furosemide | 11 | $25 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $515 | $42,05268 claims |
| AstraZenecaBreztri Aerosphere | $504 | $26,61927 claims |
| Boehringer IngelheimSpiriva Respimat | $233 | $9,13319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in Fairfax
- Priya PatelFairfax$36K
- George BazacoFairfax$16K
- Marla ShumanFairfax$15K
- Steven NathanFalls Church$1.5M
- Omar MinaiHopewell$1.3M
- Rabih HalabiFalls Church$604K
- Eric LibreAnnandale$302K
- Sujoy GillRichmond$296K
- Imre NothCharlottesville$256K
- Carlos SilvaChesapeake$245K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.